NRX Pharmaceuticals Inc.-CW22NRXPWPreferred / convertible
13F holders, Q1 2024 (March 31)4holders
$0.18avg. 13F price*
At the end of Q1 2024, 4 institutions reported holding NRX Pharmaceuticals Inc.-CW22 (NRXPW) in their 13F filings. The largest holders were Susquehanna International Group, LLP ($2K), Wolverine Asset Management LLC ($404) and UBS Group AG ($13).
- Company
- NRX Pharmaceuticals Inc.-CW22
- CUSIP
- 629444118
- Latest filing quarter
- Q1 2026
History
Number of 13F holders
Total Exit/New Position Q1 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 2 | $2K |
| Exits | 1 | $2K |
Ownership 4 holders
| Susquehanna International Group, LLP | — | New | 13,436 | $2K |
| Wolverine Asset Management LLC | — | Reduce -71.8% | 2,157 | $404 |
| UBS Group AG | — | New | 69 | $13 |
| Tower Research Capital LLC (TRC) | — | No change | 15 | $3 |
"% of holder's portfolio" is NRXPW's weight in each manager's 13F, not the share of NRX Pharmaceuticals Inc.-CW22 the manager owns.